ABSTRACT
Advances in our understanding of the pathophysiology of rheumatic and immunologic diseases have led to improved therapies, such as tumor necrosis factor inhibitors and bisphosphonates. These drugs can not only alleviate symptoms but also alter the course of the disease. However, they also have significant potential side effects, which mandate, more than ever, correct diagnosis and vigilant monitoring for toxicity.
Footnotes
↵* The author has indicated that he has received grant or research support from the Novartis, Smith-Kline, Centocor, Searle, and Merck corporations, and that this article discusses therapies that are not yet approved by the Food and Drug Administration for the use under discussion or that are still under investigation.
- Copyright © 2001 The Cleveland Clinic Foundation. All Rights Reserved.